GE Healthcare, makers of awesome imaging products, is announcing the opening of an Integrated Development Centre at the Manipal Hospital in Bangalore, India. The facility will take part in multi-center international research in an effort to bring new technologies to market sooner…
The IDC in Bangalore is expected to conduct around 1, 000 scans annually as part of the planned clinical trials and will be a part of a series of global multi-country clinical studies in the United States, the European Union and several other countries. Over time, GE Healthcare will create more IDCs in key strategic locations globally.
The research efforts of GE Healthcare’s Medical Diagnostics R&D team are currently focused on functional and molecular imaging agents that help doctors evaluate the physiology of disease and make treatment decisions earlier with confidence.
Information obtained from this site will be combined with data from other centres globally and contribute towards the development of new contrast and molecular imaging agents or new indications for existing agents.
The first studies will focus on Visipaque (iodixanol), an isosmolar contrast agent that was launched globally by GE Healthcare in 1996. Visipaque has been used in millions of x-ray and computer tomography procedures till date.
Under the terms of the collaboration, physicians at Manipal Hospital will act as study investigators and provide clinical and imaging services and administration in the hospital.
More from the Press Release (which apparently hasn’t launched on GE’s page, only through the Indian news channels)